Nasdaq listing
Published: March 22, 2017
Top stories
Financing – May 22, 2026
The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap.
Collaboration – May 20, 2026
Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region’s life science development.
Clinical Trials – May 20, 2026
Oncopeptides’ clinical trial application for the “Window-of-Opportunity” (WoO) study in glioblastoma has been formally approved in Norway.
New Market – May 20, 2026
The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.
Related posts
This site uses cookies